250 related articles for article (PubMed ID: 18226802)
1. Vitreous penetration of orally administered valacyclovir.
Huynh TH; Johnson MW; Comer GM; Fish DN
Am J Ophthalmol; 2008 Apr; 145(4):682-6. PubMed ID: 18226802
[TBL] [Abstract][Full Text] [Related]
2. Vitreous penetration of orally administered famciclovir.
Chong DY; Johnson MW; Huynh TH; Hall EF; Comer GM; Fish DN
Am J Ophthalmol; 2009 Jul; 148(1):38-42.e1. PubMed ID: 19375688
[TBL] [Abstract][Full Text] [Related]
3. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration.
Fiscella RG; Lai WW; Buerk B; Khan M; Rodvold KA; Pulido JS; Labib S; Shapiro MJ; Blair NP
Ophthalmology; 2004 Jun; 111(6):1191-5. PubMed ID: 15177970
[TBL] [Abstract][Full Text] [Related]
4. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
7. Multiple oral dosing of valacyclovir in horses and ponies.
Garré B; Baert K; Nauwynck H; Deprez P; De Backer P; Croubels S
J Vet Pharmacol Ther; 2009 Jun; 32(3):207-12. PubMed ID: 19646083
[TBL] [Abstract][Full Text] [Related]
8. Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study.
Liu T; Jain A; Fung M; Vinnard C; Ivaturi V
Curr Eye Res; 2017 Jul; 42(7):1035-1038. PubMed ID: 28358222
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
11. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS.
Dias C; Nashed Y; Atluri H; Mitra A
Curr Eye Res; 2002 Oct; 25(4):243-52. PubMed ID: 12658558
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
13. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection.
Bras AP; Sitar DS; Aoki FY
Can J Clin Pharmacol; 2001; 8(4):207-11. PubMed ID: 11743593
[TBL] [Abstract][Full Text] [Related]
14. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
[TBL] [Abstract][Full Text] [Related]
15. Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method.
Yadav M; Upadhyay V; Singhal P; Goswami S; Shrivastav PS
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Mar; 877(8-9):680-8. PubMed ID: 19246256
[TBL] [Abstract][Full Text] [Related]
16. Vitreous penetration of orally administered gatifloxacin in humans.
Hariprasad SM; Mieler WF; Holz ER
Trans Am Ophthalmol Soc; 2002; 100():153-9. PubMed ID: 12545689
[TBL] [Abstract][Full Text] [Related]
17. Selective and rapid liquid chromatography/negative-ion electrospray ionization mass spectrometry method for the quantification of valacyclovir and its metabolite in human plasma.
Kasiari M; Gikas E; Georgakakou S; Kazanis M; Panderi I
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 864(1-2):78-86. PubMed ID: 18295558
[TBL] [Abstract][Full Text] [Related]
18. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
Beutner KR
Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
Warren T; Harris J; Brennan CA
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
[TBL] [Abstract][Full Text] [Related]
20. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.
Hariprasad SM; Mieler WF; Holz ER; Gao H; Kim JE; Chi J; Prince RA
Arch Ophthalmol; 2004 Jan; 122(1):42-7. PubMed ID: 14718293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
